Fortress Biotech Inc FBIO.OQ FBIO.O is expected to show a fall in quarterly revenue when it reports results on March 31 (estimated) for the period ending December 31 2024
The Bay Harbor Islands Florida-based company is expected to report a 18.3% decrease in revenue to $16.297 million from $19.95 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Fortress Biotech Inc is for a loss of 75 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Fortress Biotech Inc is $16.00, above its last closing price of $1.73.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.59 | -0.59 | -0.76 | Missed | -27.7 |
Jun. 30 2024 | -1.14 | -1.22 | -0.73 | Beat | 40.3 |
Mar. 31 2024 | -1.69 | -1.73 | -1.03 | Beat | 40.5 |
Dec. 31 2023 | -1.67 | -1.97 | -1.28 | Beat | 34.9 |
Sep. 30 2023 | -3.12 | -3.21 | -0.94 | Beat | 70.7 |
Jun. 30 2023 | -3.31 | -3.41 | -3.60 | Missed | -5.5 |
Mar. 31 2023 | -3.38 | -3.00 | -3.15 | Missed | -5 |
Dec. 31 2022 | -3.43 | -3.37 | -4.46 | Missed | -32.2 |
This summary was machine generated March 28 at 20:27 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。